Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Stelara (ustekinumab) and Rinvoq (upadacitinib) are both medications used to treat autoimmune and inflammatory conditions, such as ulcerative colitis and psoriatic arthritis. However, they belong to different medication classes. Stelara is an interleukin antagonist that blocks proteins in your immune system to lower inflammation, while Rinvoq is a Janus kinase (JAK) inhibitor that blocks the JAK enzyme to reduce inflammation. Stelara is given as an injection, either under the skin or through an intravenous (IV) infusion, and is typically administered every 8 to 12 weeks. Rinvoq, on the other hand, is taken orally once a day as a tablet or liquid. Stelara is available for both adults and children as young as 6 years old, while Rinvoq can be used in adults and children as young as 2 years old for certain conditions. Common side effects of Stelara include common cold symptoms and headaches, whereas Rinvoq may cause upper respiratory infections and acne. Both medications can increase your risk of infections. And both medications are available only as brand-name products.
Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor. It's used to treat certain inflammatory conditions, such as rheumatoid arthritis (RA), ulcerative colitis (UC), and eczema (atopic dermatitis). But it's not a first-choice option and typically only prescribed when other treatments haven't worked well. Rinvoq (upadacitinib) is taken by mouth, usually once daily. It's available as an extended-release tablet (Rinvoq) and an oral solution (Rinvoq LQ), but the two formulations aren't interchangeable. Side effects include a higher risk of infections, acne, and nausea.
Indications of Stelara vs. Rinvoq
Indications for
•Moderate-to-severe plaque psoriasis (Ps) - adults and children 6 years and older